Epcoritamab SC With Rituximab plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma, Including Patients With POD24: Updated Results From EPCORE NHL-2

被引：0

作者：

Merryman, Reid W. ^{[1
]}

Belada, David ^{[2
,3
]}

Sureda, Anna ^{[4
]}

Leppa, Sirpa ^{[5
,6
]}

Vermaat, Joost S. P. ^{[7
]}

Holte, Harald ^{[8
,9
]}

Hutchings, Martin ^{[10
]}

Lugtenburg, Pieternella ^{[11
]}

de Vos, Sven ^{[12
]}

Abrisqueta, Pau ^{[13
]}

Nijland, Marcel ^{[14
,15
]}

Christensen, Jacob Haaber ^{[16
]}

Wahlin, Bjorn E. ^{[17
]}

Linton, Kim M. ^{[18
,19
]}

Wang Liwei ^{[20
]}

Abbas, Aqeel ^{[20
]}

Rana, Ali ^{[20
]}

Quadri, Syed ^{[21
]}

Falchi, Lorenzo ^{[22
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Univ Hosp, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic

[3] Fac Med, Hradec Kralove, Czech Republic

[4] Univ Barcelona, IDIBELL, Inst Catala Oncol, Hosp Duran i Reynals, Barcelona, Spain

[5] Univ Helsinki, Helsinki, Finland

[6] Helsinki Univ Hosp, Ctr Comprehens Canc, Helsinki, Finland

[7] Leiden Univ, Med Ctr, Leiden, Netherlands

[8] Oslo Univ Hosp, Oslo, Norway

[9] KG Jebsen Ctr B Cell Malignancies, Oslo, Norway

[10] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark

[11] Erasmus MC Canc Inst, Univ Med Ctr, Dept Hematol, Lunenburg Lymphoma Phase Consortium HOVON LLPC 1, Rotterdam, Netherlands

[12] Ronald Reagan Univ Calif Los Angeles Med Ctr, Los Angeles, CA USA

[13] Hosp Univ Vall dHebron, Barcelona, Spain

[14] Univ Med Ctr Groningen, Groningen, Netherlands

[15] Univ Groningen, Groningen, Netherlands

[16] Odense Univ Hosp, Odense, Denmark

[17] Karolinska Inst, Stockholm, Sweden

[18] Christie NHS Fdn Trust, Manchester, Lancs, England

[19] Manchester Canc Res Ctr, Manchester, Lancs, England

[20] Genmab, Plainsboro, NJ USA

[21] AbbVie, N Chicago, IL USA

[22] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, New York, NY USA

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2023年 / 98卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P-059

引用

页码：S37 / S38

页数：2

共 50 条

[21] Subcutaneous epcoritamab in Japanese patients with relapsed/refractory diffuse large B-cell lymphoma: EPCORE NHL-3 data
Izutsu, Koji
Kumode, Takahiro
Yuda, Junichiro
Nagai, Hirokazu
Mishima, Yuko
Suehiro, Youko
Yamamoto, Kazuhito
Fujisaki, Tomoaki
Ishitsuka, Kenji
Ishizawa, Kenichi
Ikezoe, Takayuki
Nishikori, Momoko
Akahane, Daigo
Fujita, Jiro
Wu, Jun
Broberg, Per
Buchbjerg, Jeppe
Fukuhara, Noriko
ANNALS OF ONCOLOGY, 2023, 34 : S1389 - S1389
[22] Updated Results of a Prospective Study: Rituximab and Lenalidomide Plus Chidamide (RLC) for Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma
Li, Cong
Hu, Huixian
Lei, Tao
Yu, Haifeng
Chen, Xi
Peng, Shuailing
Han, Shuiyun
Yang, Haiyan
BLOOD, 2023, 142
[23] Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL).
Andorsky, David Jacob
Yacoub, Abdulraheem
Melear, Jason M.
Coleman, Morton
Kolibaba, Kathryn S.
Brooks, Heather Dawn
Bitran, Jacob D.
Fanning, Suzanne R.
Lansigan, Frederick
Ricker, Justin L.
Foon, Kenneth A.
Liu, Dongfang
Llorente, Mary
Li, Jiahui
Sharman, Jeff Porter
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[24] Subcutaneous Epcoritamab in Patients with Relapsed/ Refractory Large B-Cell Lymphoma: Longer-Term Results From the Pivotal EPCORE NHL-1 Trial
Tatyana, Feldman
Yasmin, Karimi
Herve, Ghesquieres
Wojciech, Jurczak
Chan, Cheah Y.
Michael, Roost Clausen
Pieternella, Lugtenburg
David, Cunningham
Do Young, Rok
John, Lewis David
Robin, Gasiorowski
Min, Kim Tae
Marjolein, van der Poel
Michelle, Limei Poon
Kim, Linton M.
Anna, Sureda
Martin, Hutchings
Mariana, Cota Stirner
Mariana, Sacchi
Catherine, Thieblemont
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S49 - S50
[25] Subcutaneous Epcoritamab in Relapsed or Refractory Large B-Cell Lymphoma: Pivotal Results from the Phase 2 EPCORE NHL-1 Trial
Catherine, Thieblemont
Tycel, Phillips
Herve, Ghesquieres
Cheah, Chan Y.
David, Cunningham
Do, Young R.
Tatyana, Feldman
Robin, Gasiorowski Robin
Wojciech, Jurczak
Tae, Min Kim Tae M.
Lewis, David J.
Mariolein, Van der Poe
Poon, Michelle L.
Thomas, Doerr
Nurgul, Kilavuz
Menghui, Chen
Mariana, Sacchi
Martin, Hutchings
Pieternella, Lugtenburg
Roost, Clausen Michael
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S31 - S32
[26] Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6
Andorsky, David Jacob
Boccia, Ralph V.
Lash, Bradley Walter
Vaidya, Rakhee
Gandhi, Mitul
Patel, Ameet
Ibrahimi, Sami
Madueno, Fernando Manuel Vargas
Lee, Christina Y.
Naik, Seema
Haydu, J. Erika
Fesler, Mark
Osei-Bonsu, Kojo
Conte, Kristin
Doerr, Thomas
Bai, Yang
Sacchi, Mariana
Sharman, Jeff Porter
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[27] Subcutaneous Epcoritamab With R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma, Including Double-Hit/Triple-Hit Lymphoma: Updated Results From EPCORE NHL-2
Falchi, Lorenzo
Clausen, Roost Michael
Offner, Fritz
de Vos, Sven
Joshua, Brody D.
Kim, Linton M.
Snauwaert, Sylvia
Cordoba, Raul
Oki, Toshihiko
Bykhovski, Irina
Wang Liwei
Rana, Ali
Belada, David
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S50 - S50
[28] Epcoritamab plus R-CHOP in Patients With Previously Untreated (1L) High-Risk Diffuse Large B-Cell Lymphoma, Including Double-Hit/Triple-Hit Lymphoma: Updated EPCORE NHL-2 Data
Falchi, Lorenzo
Clausen, Michael Roost
Offner, Fritz
de Vos, Sven
Brody, Joshua
Linton, Kim M.
Snauwaert, Sylvia
Cordoba, Raul
Wu, Jun
Bykhovski, Irina
Rana, Ali
Belada, David
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S431 - S432
[29] A Phase III, Randomized, Double-Blind, Study of Tazemetostat or Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory Follicular Lymphoma
Salles, Gilles
Shah, Harsh
Leonard, John P.
Szanto, Attila
Chen, Jade
Bannerji, Rajat
Morschhauser, Franck
Nastoupil, Loretta J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S454 - S455
[30] A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).
Sehn, Laurie Helen
Scholz, Christian W.
Luminari, Stefano
Salar, Antonio
Wahlin, Bjorn E.
Gopal, Ajay K.
Bonnet, Christophe Marc
Paneesha, Shankara
Manzke, Oliver
Seguy, Francis
Li, Di
Huebel, Kai
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →